MEGF9

Across TCGA pan-cancer cohorts, MEGF9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEGF9 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MEGF9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MEGF9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where MEGF9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.764	0.943	.002	41	view →
PDAC	OS	Tertile	III,IV	0.047	1.000	.024	19	view →
UCEC	DFS	Median	II,III,IV	0.925	0.532	.032	4	view →
GBM	DFS	Median	All	0.874	0.624	.003	3	view →
LSCC	DFS	Tertile	II,III,IV	0.858	0.572	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEGF9–LUAD (DFS)

Open the LUAD breakdown →